((自动化翻译由路透提供，请见免责声明 )) (第 1 段增加了股份，全文增加了详细信息)
路透10月14日 - 丹麦 H Lundbeck A/S 已同意以 26 亿美元的价格收购 Longboard Pharmaceuticals ，以扩大其治疗神经罕见疾病的产品线，这使得这家美国公司的股价在盘前交易中上涨了 43.9%。
两家公司表示，灵北将以每股 60 美元的价格收购 Longboard 的全部股份，这比该股最后收盘价 38.90 美元溢价 54.2%。
Longboard公司的主要候选药物bexicaserin用于治疗与一组癫痫相关的癫痫发作，目前正处于后期开发阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.